1
Registered trials
0
Recruiting
1
Unique sponsors
1
Unique IMPs
1
Commercial trials
Drug classes (ATC)
B
Haematology (ATC B)
1
Mechanism of action (INN-stem analysis)
Unknown / small molecule
1 substance
Phase I/II:
1
Phase I/II
1 trial-
EndedRocket Pharmaceuticals Inc. CommercialAUTOLOGOUS CD34+ HAEMATOPOIETIC STEM CELLS GENETICALLY MODIFIED WITH LENTIVIRAL VECTOR ENCODING THE CD18 GENE
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Rocket Pharmaceuticals Inc. | Commercial | 1 | Phase I/II | 0 |
New trials by year
2023
1